Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

ENROLLING BY INVITATION

NCT05303532

PHASE3

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab

Sponsor: AstraZeneca

View on ClinicalTrials.gov

Summary

The rationale of the ROSY-D study is to continue to provide study treatment for patients who have participated in a parent study with Durvalumab and who are continuing to derive clinical benefit from treatment at the end of such studies, as judged by the Investigator.

Official title: ROSY-D: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab and Are Judged by the Investigator to Clinically Benefit From Continued Treatment

Key Details

Gender

All

Age Range

18 Years - 99 Years

Study Type

INTERVENTIONAL

Enrollment

214

Start Date

2022-04-19

Completion Date

2026-12-31

Last Updated

2026-03-24

Healthy Volunteers

Conditions

Cancer

Interventions

DRUG

Durvalumab

Fixed dose of 1500 mg via IV infusion upon enrollment visit and every 4 weeks thereafter.

Inclusion Criteria: The Core Protocol inclusion criteria are: * Provision of signed and dated, written Informed Consent Form (ICF). * Patient is currently deriving clinical benefit, as judged by the investigator, from continued treatment in an AstraZeneca parent study using an AstraZeneca compound that has met its endpoints, or has otherwise stopped, or the patient has reached maximum treatment duration allowed in the parent study's protocol. * Patient can receive durvalumab as a fixed dose of 1500 mg quarterly 4 weeks at study entry. There are no additional inclusion criteria for the ROSY-D sub-study. Exclusion Criteria: The Core Protocol exclusion criteria are. * Ongoing, unresolved, Grade 3 or above toxicity requiring interruption of treatment at the time of the termination of the parent study. * Currently receiving treatment with any prohibited medication(s). * Concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study. * Permanent discontinuation from the parent study due to toxicity or disease progression (increase in the severity of the disease under study and/or increases in the symptoms of a patient's condition attributable to the disease, as assessed and documented by the Investigator. Physician-defined progression can be radiological \[example: Response Evaluation Criteria in Solid Tumours\] progression or clinical progression). * Local access to commercially-available drug at no cost to the patient as permitted by local/country regulation. The additional exclusion criteria for the ROSY-D sub-study are: * Active infection including Coronavirus disease 2019 (Polymerase chain reaction confirmed and/or clinically suspected), tuberculosis, hepatitis B (known positive Hepatitis B virus (HBV) surface antigen result), hepatitis C, or Human immunodeficiency virus (HIV) (positive HIV 1/2 antibodies). * Male or female patients of reproductive potential who are not willing to employ effective birth control from study inclusion up to 90 days after the last dose of durvalumab monotherapy. * Ongoing, unresolved, Grade 2 toxicity with an inability to reduce corticosteroid to a dose of ≤ 10 mg of prednisone per day (or equivalent) within 12 weeks after last dose of study treatment/study regimen, per Toxicity Dose Modification and TMGs for Immune- mediated, Infusion-related, and Non-Immune-mediated Reactions Guidelines of the parent study.

Locations (124)

Research Site

Newport Beach, California, United States

Research Site

Denver, Colorado, United States

Research Site

Memphis, Tennessee, United States

Research Site

Rosario, Argentina

Research Site

Box Hill, Australia

Research Site

Melbourne, Australia

Research Site

Charleroi, Belgium

Research Site

Barretos, Brazil

Research Site

São José do Rio Preto, Brazil

Research Site

Sofia, Bulgaria

Research Site

Sofia, Bulgaria

Research Site

Kingston, Ontario, Canada

Research Site

Newmarket, Ontario, Canada

Research Site

Toronto, Ontario, Canada

Research Site

Beijing, China

Research Site

Changsha, China

Research Site

Hangzhou, China

Research Site

Hangzhou, China

Research Site

Nanjing, China

Research Site

Shanghai, China

Research Site

Shenyang, China

Research Site

Wenzhou, China

Research Site

Xi'an, China

Research Site

Xiamen, China

Research Site

Olomouc, Czechia

Research Site

Besançon, France

Research Site

Bordeaux, France

Research Site

Brest, France

Research Site

Dijon, France

Research Site

Lyon, France

Research Site

Marseille, France

Research Site

Montpellier, France

Research Site

Rennes, France

Research Site

Rouen, France

Research Site

Saint-Herblain, France

Research Site

Strasbourg, France

Research Site

Toulouse, France

Research Site

Tours, France

Research Site

Villejuif, France

Research Site

Gütersloh, Germany

Research Site

Münster, Germany

Research Site

Oldenburg, Germany

Research Site

Athens, Greece

Research Site

Budapest, Hungary

Research Site

Győr, Hungary

Research Site

Székesfehérvár, Hungary

Research Site

Chennai, India

Research Site

Arezzo, Italy

Research Site

Bari, Italy

Research Site

Catania, Italy

Research Site

Meldola, Italy

Research Site

Milan, Italy

Research Site

Modena, Italy

Research Site

Padova, Italy

Research Site

Pisa, Italy

Research Site

Roma, Italy

Research Site

Roma, Italy

Research Site

Bunkyō City, Japan

Research Site

Fukuoka, Japan

Research Site

Kanazawa, Japan

Research Site

Kōtoku, Japan

Research Site

Nagoya, Japan

Research Site

Okayama, Japan

Research Site

Saga, Japan

Research Site

Sunto-gun, Japan

Research Site

Kuching, Malaysia

Research Site

Aguascalientes, Mexico

Research Site

Mexico City, Mexico

Research Site

Mérida, Mexico

Research Site

Quezon City, Philippines

Research Site

Bialystok, Poland

Research Site

Bydgoszcz, Poland

Research Site

Elblag, Poland

Research Site

Lodz, Poland

Research Site

Lodz, Poland

Research Site

Olsztyn, Poland

Research Site

Szczecin, Poland

Research Site

Warsaw, Poland

Research Site

Suceava, Romania

Research Site

Moscow, Russia

Research Site

Moscow, Russia

Research Site

Nizhny Novgorod, Russia

Research Site

Novosibirsk, Russia

Research Site

Omsk, Russia

Research Site

Saint Petersburg, Russia

Research Site

Saint Petersburg, Russia

Research Site

Busan, South Korea

Research Site

Gwangju, South Korea

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

Barcelona, Spain

Research Site

Barcelona, Spain

Research Site

Girona, Spain

Research Site

Madrid, Spain

Research Site

Marbella, Spain

Research Site

Santiago de Compostela, Spain

Research Site

Valencia, Spain

Research Site

Lausanne, Switzerland

Research Site

Taichung, Taiwan

Research Site

Taichung, Taiwan

Research Site

Tainan, Taiwan

Research Site

Taipei, Taiwan

Research Site

Taoyuan District, Taiwan

Research Site

Bangkok, Thailand

Research Site

Chiang Mai, Thailand

Research Site

Hat Yai, Thailand

Research Site

Ankara, Turkey (Türkiye)

Research Site

Ankara, Turkey (Türkiye)

Research Site

Ankara, Turkey (Türkiye)

Research Site

Bursa, Turkey (Türkiye)

Research Site

Istanbul, Turkey (Türkiye)

Research Site

Izmir, Turkey (Türkiye)

Research Site

Chernivtsi, Ukraine

Research Site

Dnipro, Ukraine

Research Site

Ivano-Frankivsk, Ukraine

Research Site

Kyiv, Ukraine

Research Site

Uzhhorod, Ukraine

Research Site

Vinnytsia, Ukraine

Research Site

London, United Kingdom

Research Site

Sheffield, United Kingdom

Research Site

Hanoi, Vietnam

Research Site

Ho Chi Minh City, Vietnam

Research Site

Hồ Chí Minh, Vietnam

Clinical Research Directory

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab

Summary

Key Details

Conditions

Interventions

Eligibility Criteria

Locations (124)